Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells

19 Mar 2026 12:49 CET

Arctic Bioscience announces that new research on herring roe oil (HRO) and
phospholipid esters from herring roe (PEHeRo) has been accepted for publication
in the Journal of Lipid Research, an internationally recognized scientific
journal in the field of lipid biology.

The study shows that HRO and its phospholipids (PEHeRo) activates the body's own
inflammation-resolving mechanisms by increasing the production of specialized
pro-resolving mediators (SPMs) in human immune cells and in a skin cell model
relevant for psoriasis. SPMs are naturally occurring molecules derived from
omega-3 fatty acids that help the body calm and resolve inflammation.

"We are very pleased to see these results published in a high-quality,
peer-reviewed journal. This reinforces the strong scientific foundation built by
our team. The findings further strengthen our understanding of how our
investigational medicine HRO350 may help the body regulate inflammation, which
is directly relevant for diseases like psoriasis," says CEO Christer L.
Valderhaug.

The study demonstrates that treatment with herring roe phospholipids leads to a
clear increase in several lipid mediator families, including mediators known to
support resolution of inflammation and tissue repair. The results were
consistent across both immune cells and skin cells involved in psoriatic disease
processes.

"This research provides important insight into how HRO350 may work at a cellular
level in psoriasis and generally in immune-mediated diseases. We are especially
encouraged by the consistent activation of inflammation-resolving pathways. This
supports the scientific foundation of our clinical development program," says
Medical Director Runhild Gammelsæter.

HRO350 is currently in development as a potential new oral treatment option for
mild-to-moderate psoriasis, a large patient population in need of therapies with
favourable safety and tolerability profiles.

"Our R&D team has devoted a lot of time and resources to this project, and it is
exciting to see the extracts we produce show targeted biological effects in
state-of-the-art laboratory models," says CTO Daniele Mancinelli.

The research was carried out in collaboration with William Harvey Research
Institute (UK), Nofima (Norway), and Møreforsking (Norway), and was partly
supported by a grant from the Norwegian Research Council (project no. 327953).

Reference:
Ringheim-Bakka TA, Saliani A, Østbye TKK, Mildenberger J, Dooley M, Busygina M,
Pedersen ME, Solberg NT, Dalli J, Gammelsæter R. Herring roe PLs promote SPM
biosynthesis in macrophages and a keratinocyte/fibroblast co-culture as model of
psoriasis. Journal of Lipid Research (2026).

DOI: https://doi.org/10.1016/j.jlr.2026.101016

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site